{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:19:31Z","timestamp":1793521171516,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"name":"Corvidia Therapeutics, Inc"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2021,1]]},"abstract":"\n Significance Statement<\/jats:title>\n Patients with CKD who are on hemodialysis are hyporesponsive to erythropoiesis-stimulating agents (ESAs) because of anemia of inflammation mediated by IL-6\u2013induced expression of hepcidin, an iron regulatory hormone. Reducing ESA usage to decrease ESA-related cardiovascular risk, especially with high ESA doses, is a clinical goal of nephrologists. In this randomized, phase 1\/2 trial in patients with inflammation on hemodialysis, the authors show that ziltivekimab, a novel anti\u2013IL-6 ligand antibody, reduced markers of inflammation, decreased ESA usage, and increased serum albumin, which might lead to a reduction in overall cardiovascular risk. Because current anemia treatments do not reduce inflammation, the availability of an anti-inflammatory therapy that also improves iron utilization and reduces the need for escalating doses of ESAs could represent an important advancement in the care of patients on hemodialysis.<\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Patients with CKD who are on hemodialysis are hyporesponsive to erythropoiesis-stimulating agents (ESAs) because of anemia of inflammation. Interleukin-6 (IL-6) induced hepcidin expression is a key mediator of such inflammation.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This phase 1\/2, placebo-controlled trial assessed effects of ziltivekimab, a novel anti\u2013IL-6 ligand antibody, in patients on hemodialysis with rs855791, a single nucleotide polymorphism of the\n TMPRSS6<\/jats:italic>\n gene that is hypothesized to heighten susceptibility to IL-6\u2013mediated inflammatory effects. After a screening period documenting stable ESA and iron dosing, we randomized 61 patients with elevated IL-6 (\u22654 pg\/ml) to receive placebo or ziltivekimab (doses of 2, 6, or 20 mg), administered intravenously every 2 weeks for 12 weeks during hemodialysis. ESA dose adjustments were allowed after 4 weeks. We analyzed safety and effects on inflammation, iron metabolism, serum albumin, and anti-drug antibodies.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n No patient experienced dose-limiting toxicity. Four patients (two each in the 6- and 20-mg cohorts) died of a treatment-emergent adverse event. Compared with patients receiving placebo, those receiving ziltivekimab experienced significantly greater reductions of high-sensitivity C-reactive protein, serum amyloid A, and fibrinogen from baseline to end of treatment. Median ESA usage decreased by 15,000, 15,000, or 33,000 IU\/wk per patient in the 2-, 6-, and 20-mg ziltivekimab cohorts, respectively, compared with no change in the placebo group. We also noted significant dose responses for decreased ESA resistance index and increased serum iron, total iron binding capacity, transferrin saturation, and serum albumin.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Ziltivekimab significantly improved markers of inflammation, reduced ESA requirements, and increased serum albumin in patients on hemodialysis with inflammation and hyporesponsiveness to ESA therapy.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number<\/jats:title>\n Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001, NCT02868229<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.2020050595","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T15:55:37Z","timestamp":1607010937000},"page":"211-222","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":84,"title":["Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1\/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1681","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct02868229","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct01559103","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03126318","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02868229","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Pablo E.","family":"Pergola","sequence":"first","affiliation":[{"name":"Renal Associates, P.A., San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Devalaraja","sequence":"additional","affiliation":[{"name":"Corvidia Therapeutics, Inc., Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Donald and Barbara Zucker School of Medicine, Great Neck, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine Disease and Hypertension, University of Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana S.","family":"Mathur","sequence":"additional","affiliation":[{"name":"Mathur Consulting, Woodside, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Smith","sequence":"additional","affiliation":[{"name":"Nephrology Associates, Augusta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Lo","sequence":"additional","affiliation":[{"name":"Corvidia Therapeutics, Inc., Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Herzog","sequence":"additional","affiliation":[{"name":"Corvidia Therapeutics, Inc., Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Pandion Therapeutics, Inc., Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[{"name":"Corvidia Therapeutics, Inc., Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"B1-20240826","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"B2-20240826","first-page":"ii32","article-title":"Section IV. Failure to respond to treatment","volume":"19","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 8","key":"B3-20240826","doi-asserted-by":"crossref","first-page":"viii2","DOI":"10.1093\/ndt\/gfh1109","article-title":"Inflammation and resistance to erythropoiesis-stimulating agents\u2014What do we know and what needs to be clarified?","volume":"20","author":"Smrzova","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"B4-20240826","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1525-139X.2006.00172.x","article-title":"Erythropoietin resistance in the treatment of the anemia of chronic renal failure","volume":"19","author":"Priyadarshi","year":"2006","journal-title":"Semin Dial"},{"key":"B5-20240826","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/ndt\/gfq802","article-title":"Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: Results from the RISCAVID study","volume":"26","author":"Panichi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B6-20240826","doi-asserted-by":"crossref","first-page":"e0147328","DOI":"10.1371\/journal.pone.0147328","article-title":"ESA hyporesponsiveness is associated with adverse events in maintenance hemodialysis (MHD) patients, but not with iron storage","volume":"11","author":"Kuragano","year":"2016","journal-title":"PLoS One"},{"key":"B7-20240826","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"B8-20240826","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"B9-20240826","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/j.seminhematol.2009.06.001","article-title":"Iron sequestration and anemia of inflammation","volume":"46","author":"Ganz","year":"2009","journal-title":"Semin Hematol"},{"key":"B10-20240826","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","article-title":"Interleukin-6 induces hepcidin expression through STAT3","volume":"108","author":"Wrighting","year":"2006","journal-title":"Blood"},{"key":"B11-20240826","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ng.462","article-title":"Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels","volume":"41","author":"Chambers","year":"2009","journal-title":"Nat Genet"},{"key":"B12-20240826","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1182\/blood-2011-06-364034","article-title":"TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals","volume":"118","author":"Nai","year":"2011","journal-title":"Blood"},{"key":"B14-20240826","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/ndt\/17.9.1684","article-title":"Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment","volume":"17","author":"Pecoits-Filho","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"B15-20240826","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.ajkd.2004.09.018","article-title":"Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients","volume":"45","author":"Rao","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B16-20240826","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ki.2009.503","article-title":"Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease","volume":"77","author":"Barreto","year":"2010","journal-title":"Kidney Int"},{"key":"B17-20240826","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1681\/ASN.V7122654","article-title":"The evaluation of iron status in hemodialysis patients","volume":"7","author":"Fishbane","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"B18-20240826","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients\u2019 Response to IV Iron with Elevated Ferritin (DRIVE) study","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B19-20240826","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: Results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B20-20240826","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1385-7258(52)50043-X","article-title":"The asymptotic normality and consistency of Kendall\u2019s test against trend, when ties are present in ranking","volume":"14","author":"Terpstra","year":"1952","journal-title":"Indag Math"},{"key":"B21-20240826","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/biomet\/41.1-2.133","article-title":"A distribution-free k-sample test against ordered alternatives","volume":"41","author":"Jonckheere","year":"1954","journal-title":"Biometrika"},{"key":"B22-20240826","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000095873","article-title":"Does hepcidin affect erythropoiesis in hemodialysis patients?","volume":"116","author":"Eleftheriadis","year":"2006","journal-title":"Acta Haematol"},{"key":"B23-20240826","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1525-139X.2008.00532.x","article-title":"The role of hepcidin in iron homeostasis and anemia in hemodialysis patients","volume":"22","author":"Eleftheriadis","year":"2009","journal-title":"Semin Dial"},{"key":"B24-20240826","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0272-6386(03)00915-6","article-title":"Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients","volume":"42","author":"Kalantar-Zadeh","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B25-20240826","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ncpneph0655","article-title":"Mechanisms of disease: Erythropoietin resistance in patients with both heart and kidney failure","volume":"4","author":"van der Putten","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"B27-20240826","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/ndt\/gft021","article-title":"Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: The potential role of inflammation","volume":"28","author":"Icardi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B28-20240826","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.4081\/hr.2019.8183","article-title":"Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients","volume":"11","author":"Amnuay","year":"2019","journal-title":"Hematol Rep"},{"key":"B29-20240826","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.3390\/nu11102424","article-title":"Anemia of inflammation with an emphasis on chronic kidney disease","volume":"11","author":"Begum","year":"2019","journal-title":"Nutrients"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2020050595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:24:32Z","timestamp":1786130672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2020050595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2020050595","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]},"assertion":[{"value":"2020-05-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}